Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyColorado Rocky Mountain — Korsuva Coverage Update …
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy CSOH2026D00115.D

    Korsuva (difelikefalin) — Medical Benefit Drug Coverage Criteria (Ohio)

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CSOH2026D00115.D alerts

    Get alerted when Policy CSOH2026D00115.D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit drug coverage criteria for Korsuva (difelikefalin) for adults with moderate-to-severe CKD-associated pruritus receiving hemodialysis in Ohio.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyKorsuva (difelikefalin) — Medical Benefit Drug Coverage Criteria (Ohio)
    Policy CodePolicy CSOH2026D00115.D
    Change TypeAdded diagnosis codesadministrative revision
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation that the patient is on hemodialysis, has moderate-to-severe CKD-associated pruritus, and meets initial or continuation criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Applicable ICD-10 diagnosis codes L29.89 and L29.9 were added to the policy.

    Supporting information: previous policy version CSOH2025D00115.C was archived.

    12 monthsmax initial auth (months)
    12 monthsmax reauth (months)
    0.5 mcg/kgIV dose (trials)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3x/week
    dosing freq
    >=4-point WI-NRSefficacy threshold

    Coverage Criteria for Korsuva (difelikefalin)

    Initial Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Initial Therapy Criteria: Diagnosis of moderate-to-severe pruritus associated with chronic kidney disease; patient is on hemodialysis; pruritus is not attributed to a cause other than end-stage renal disease or its complications (e.g., pruritic dermatological disease, cholestatic liver disease); pruritus is not limited to occurring only during the dialysis session; pruritus is not localized to just the palms of the hands; history of failure, contraindication, or intolerance to other pruritus treatments (e.g., antihistamines, corticosteroids, gabapentin, pregabalin, capsaicin); prescribed by or in consultation with a nephrologist; dosing is in accordance with the United States Food and Drug Administration (FDA)-approved labeling; initial authorization will be for no longer than 12 months

    Continuation of Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Continuation Criteria: Documentation of a positive clinical response (i.e., reduction in itch from baseline); prescribed by or in consultation with a nephrologist; dosing is in accordance with the United States Food and Drug Administration approved labeling; reauthorization will be for no longer than 12 months

    Korsuva (difelikefalin) has not been studied in patients receiving peritoneal dialysis and is not recommended for use in this population. Requests for treatment of individuals on peritoneal dialysis may be denied because the safety and effectiveness of Korsuva in that setting have not been established.

    Coverage is limited to pruritus that is attributable to end-stage renal disease (CKD-associated pruritus). Use of Korsuva for itching caused by other dermatologic or systemic conditions, or when pruritus occurs only during dialysis sessions or is limited to the palms, is not supported by the coverage criteria and would not meet medical necessity. Approval also requires documented failure, intolerance, or contraindication to other pruritus treatments and that the request be consistent with the policy’s prescribing and documentation requirements.

    Coding and Clinical Thresholds

    Covered HCPCS CodesHCPCSCovered
    J0879Injection, difelikefalin, 0.1 microgram
    Applicable Diagnosis CodesICD-10
    L29.89Other pruritus
    L29.9Pruritus, unspecified
    WI-NRS improvement threshold — primary efficacy endpoint
    Primary efficacy endpoint (trial definition)Proportion of subjects achieving a 4-point or greater improvement from baseline in the weekly mean of the daily 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) at Week 12.
    WI-NRS scalePatient-reported daily 24-hour Worst Itching Intensity Numerical Rating Scale scored 0 (no itch) to 10 (worst itch imaginable).
    Assessment timingWeekly mean of daily WI-NRS scores with primary analysis at Week 12 after 12 weeks of treatment.
    Dosing context in trialsIntravenous bolus 0.5 mcg/kg given into the venous line at the end of each hemodialysis session, three times weekly for 12 weeks (context for endpoint measurement).

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required (HCPCS J0879)

    Prior authorization is required for Korsuva (difelikefalin). The request must include documentation that meets either the Initial Therapy or Continuation of Therapy criteria; bill using HCPCS code J0879 (Injection, difelikefalin, 0.1 microgram).

    • Initial authorization up to 12 months; reauthorization up to 12 months.
    Step Therapy

    Step therapy — prior failure/intolerance required

    Policy requires a documented history of failure, contraindication, or intolerance to other pruritus treatments (examples provided in policy) before approval of Korsuva.

    • Examples listed: antihistamines, corticosteroids, gabapentin, pregabalin, capsaicin.

    Background and Clinical Context

    Chronic kidney disease–associated pruritus (CKD-aP), often called uremic pruritus, is common among people receiving hemodialysis; approximately 20–40% of patients report moderate-to-severe symptoms. CKD-aP negatively affects sleep and mood, reduces quality of life, and has been linked with higher infection risk and increased mortality. The pathogenesis is not fully understood but likely involves metabolic and immune disturbances and imbalance of the opioid system, with peripheral kappa opioid receptors implicated—providing the rationale for using a kappa opioid receptor agonist such as difelikefalin (Korsuva) in hemodialysis patients. Korsuva is indicated for adults with moderate-to-severe CKD-associated pruritus who are undergoing hemodialysis; however, it has not been studied in patients on peritoneal dialysis and is not recommended for that population.

    Definitions and Limitations of Use

    Moderate-to-severe pruritus associated with chronic kidney disease — definition
    DefinitionPatient-reported significant itching attributed to end-stage renal disease (chronic kidney disease-associated pruritus) occurring beyond the dialysis session and not due to other dermatologic or systemic causes.
    Clinical contextOccurs in adults undergoing hemodialysis and may be persistent between dialysis sessions, not limited to the palms only.
    Documentation requiredDiagnosis must be documented and pruritus should not be attributed to causes other than ESRD or its complications (e.g., pruritic dermatological disease, cholestatic liver disease).
    Limitation of use — peritoneal dialysis
    Limitation of useKorsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.
    Implication for coverage
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyKorsuva (difelikefalin) — Medical Benefit Drug Coverage Criteria (Ohio)
    Policy CodePolicy CSOH2026D00115.D
    Change TypeAdded diagnosis codesadministrative revision
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation that the patient is on hemodialysis, has moderate-to-severe CKD-associated pruritus, and meets initial or continuation criteria.
    SourceLink
    On This Page
    Coverage Criteria for Korsuva (difelikefalin)Coding and Clinical ThresholdsProvider Actions, Prior Authorization, and DocumentationBackground and Clinical ContextDefinitions and Limitations of Use
    Documentation Required

    Required clinical documentation to support PA

    Include clinical documentation to support the request: diagnosis of moderate-to-severe CKD-associated pruritus, confirmation the patient is on hemodialysis, evidence pruritus is not due to another cause, and documentation of prior treatment failure/contraindication/intolerance.

    • Evidence of nephrology involvement (prescribed by or in consultation with a nephrologist).
    • Dosing must be consistent with FDA-approved labeling.
    Documentation Required

    Reauthorization — document positive clinical response

    For continuation/reauthorization, provide documentation of a positive clinical response, defined as reduction in itch from baseline; reauthorization requests must also show nephrology involvement and FDA-consistent dosing.

    • Reauthorization will be for no longer than 12 months.
    • Documentation of improvement must be included with the request.
    Denial Risk

    Denial risk for criteria nonconformance

    Requests that do not meet the coverage criteria risk denial. Examples include patients not on hemodialysis, pruritus attributed to non‑ESRD causes, pruritus limited only to dialysis sessions or only to the palms, lack of prior failure/intolerance/contraindication to other therapies, or therapy not prescribed by/with nephrology involvement or dosed per FDA labeling.

    • Nonconformance with any Initial or Continuation criterion may result in denial.
    Denial Risk

    Peritoneal dialysis — not recommended; possible denial

    Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population; requests for patients on peritoneal dialysis may be denied.

    • Peritoneal dialysis use is a stated limitation of use in the policy.
    Use in patients on peritoneal dialysis may be denied per policy exclusions.
    FDA statement sourceLimitation of use is specified in the FDA information section of the policy.